COMPARISON OF EMPAGLIFLOZIN-LINAGLIPTIN WITH EMPAGLIFLOZIN- METFORMIN COMBINATION THERAPY IN REDUCTION OF BODY WEIGHT IN T2DM

Abstract

Diabetic patients need the rational approaches that can provide in order to design an effective treatment plan against increase weight gain. Combinations of anti-diabetic medications may assist diabetic patients in selecting the optimal treatment for their condition. To determine the most effective anti-diabetic drug combinations for the treatment of diabetes along with its complications like nephropathy, retinopathy, and neuropathy and increase body mass index, one of the most pressing public health issues of the twenty-first century. Therefore the aim of the present study was to compare empagliflozin-linagliptin with empagliflozin- metformin combination for the reduction of body weight in T2DM. The current randomized control trial was conducted in National Medical Center, Karachi from December 2022 to February 2023. Total 200 diagnosed patients of type 2 diabetes mellitus was enrolled in which 100 were male and 100 were females. The patients were divided two groups on the basis of their treatment option; group A Empagliflozin with metformin and group B Empagliflozin with linagliptin. All the basic information of patients (such as name, age (years), sex (male / female), co-morbidities (cancer, trauma, hepatic impairment, renal dysfunction, cardiovascular events and many others), body mass index, glycated hemoglobin (HbA1c), RBS, LFT, RFT, Urea, creatinine, ketonuria, glucosuria, and pus cell were identified. For the analysis, descriptive statistics were calculated using SPSS version 25. At the beginning of the trial, a body mass index (BMI), wasist to hip ratio (WHR) and waist circumference (WC) was identified to evaluate the prospective effect of the medicines on weight reduction in diabetic patients. All the above parameters were approximately similar between patients of each group. At the end of 4th and 12th week, the difference in BMI, WHR and WC was identified between group A male with group B male and vice versa. The analysis shown the significant differences between groups. Moreover, group A has shown more decrease in anthropometric parameters as compared to group B. The more prominent difference was found in week 12. Moreover, the HbA1c, FBS and RBS were exhibited a degree of similarity among patients in each respective group. At the end of the 4th and 12th weeks, a discernible contrast in HbA1c, FBS and RBS was observed between male/female participants in group A and those in group B. The analysis has demonstrated statistically significant differences between the groups. Furthermore, it has been observed that both the groups exhibited a greater outcome to control glucose. A significant difference was observed during the 12th week. Moreover, the safety profile was evaluated, the average of lipid profile, liver enzymes, pancreatic enzymes, of Group A and B were found approximately similar and under normal range. In conclusion, in the treatment of weight gain, it has been determined that combination of Tab Empagliflozin with Tab Metformin is more effective than combination of Tab Empagliflozin with Tab Linagliptin. Moreover, the use of combination of Tab Empagliflozin with Tab Metformin led to an improvement in the quality of life of the patient, and both combinations had better outcomes in terms of the safety profiles of diabetic patients